BioCentury
ARTICLE | Clinical News

LY334370: Delayed Phase III trial

March 8, 1999 8:00 AM UTC

Synaptic Pharmaceutical Corp. (SNAP), Paramus, N.J. Product: LY334370 Business: Neurological Therapeutic category: Neurotransmission Target: Serotonin 1F (5HT-1F) receptor Description: Selective 5HT-1...